In a nutshell This trial is looking at the effectiveness of zanubrutinib compared to ibrutinib in the treatment of patients with unresponsive or relapsed chronic lymphocytic leukemia (CLL). The main outcome to be measured will be overall response rate. The study will be carried out in the United States. The details Chronic...
Read MoreCurrently pregnant or breastfeeding-Neither Posts on Medivizor
Searching for patients to test venetoclax with azacitidine treatment for acute myeloid leukemia
In a nutshell This trial is comparing the safety and effectiveness of venetoclax (Venclexta) and azacitidine (Vidaza) with azacitidine alone in patients with acute myeloid leukemia (AML). The main outcome to be measured will be overall survival. Complete remission (no signs of cancer after treatment) will also be measured. The details Acute...
Read MoreSearching for patients with relapsed or refractory non-Hodgkin lymphoma to try a new drug
In a nutshell This study is evaluating the safety and effectiveness of a new drug called lisocabtagene maraleucel compared to standard chemotherapy for relapsed (recurrent) or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). The main outcome to be measured will be time to any disease-related complication. The...
Read MoreDoes radiotherapy improve outcomes for patients with primary breast diffuse large B-cell lymphoma?
In a nutshell This study evaluated the impact of radiotherapy on the outcomes of rituximab (Rituxan)-treated patients with primary breast diffuse large B-cell lymphoma. This study concluded that radiotherapy has significant therapeutic benefits for these patients. Some background Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare type of...
Read MoreSearching for patients with HER2 positive metastatic breast cancer to test palbociclib in combination with standard therapy.
In a nutshell This phase 3 trial aims to evaluate the effectiveness of palbociclib (Ibrance) in combination with standard treatments for HER2 positive breast cancer. The main outcome to be investigated is progression free survival. This trial is taking place in Alabama, Illinois, Iowa, Nebraska and Oklahoma in the United States. The details...
Read MoreLooking for patients with relapsed follicular, marginal zone, or mantle cell lymphoma to test the effectiveness of a rituximab and lenalidomide maintenance therapy
In a nutshell This phase 3 clinical trial will test the effectiveness of a lenalidomide (Revlimid) and rituximab (Rituxan) maintenance therapy followed by rituximab and lenalidomide or rituximab only in treating relapsed follicular, marginal zone, or mantle cell lymphoma. The primary outcome will be measured by the time to disease progression....
Read MoreLooking for patients with relapsed or refractory B-cell lymphoma to test the effectiveness of radioimmunotherapy followed by chemotherapy before stem cell transplant
In a nutshell This phase 2 clinical trial will test the safety and effectiveness of yttrium-90 (Y-90)-ibritumomab tiuxetan (Zevalin) followed by fludarabine (Fludara), total body irradiation, and donor peripheral blood stem cell transplant (PBSCT) in patients with relapsed or refractory (did not respond to treatment) B-cell lymphoma. The primary...
Read MoreSearching for newly diagnosed patients with B-lineage acute lymphoblastic leukemia to participate in a randomized immunotherapy trial
In a nutshell This phase 3 clinical trial will test the effectiveness of blinatumomab (Blincyto) with chemotherapy versus chemotherapy alone in treating patients with newly diagnosed B lineage acute lymphoblastic leukemia (ALL) that is BCR-ABL negative. The primary outcome will be measured by the overall survival. The details Blinatumomab is...
Read MoreSearching for patients with relapsed or refractory acute myeloid leukemia to test an immunotherapy
In a nutshell This phase 1 clinical trial will test the safety and effectiveness of AMV564 in treating relapsed or refractory (unresponsive to treatment) acute myeloid leukemia (AML). The primary outcome will be measured by adverse (negative) side effects and remission rate. The study is being conducted in Saint Louis, Missouri, New York City, and...
Read MoreLooking for patients with relapsed or refractory chronic lymphocytic leukemia, acute lymphoblastic leukemia, and non-Hodgkin’s lymphoma to test a CAR T-cell treatment
In a nutshell This phase 1/2 clinical trial will test the effectiveness of chimeric antigen receptor (CAR) T-cells in treating chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin’s lymphoma (NHL). The primary outcome will be measured by the response to treatment, overall survival, and the maximum tolerated...
Read MoreLooking for patients to test CAR T-cells in treating relapsed or refractory indolent non-Hodgkin lymphoma
In a nutshell This phase 2 clinical trial will test the effectiveness of axicabtagene ciloleucel (KTE-C19) in treating relapsed or refractory (unresponsive to treatment) indolent non-Hodgkin’s lymphoma (iNHL). The primary outcome will be measured by the response rate. The details Axicabtagene ciloleucel is a chimeric antigen...
Read MoreLooking for patients to test the safety of CAR T-cells in treating relapsed or refractory non-Hodgkin’s lymphoma
In a nutshell This phase 1 clinical trial will test the safety of JCAR017 CAR T-cells in treating patients with relapsed or refractory (unresponsive to treatment) B-cell non-Hodgkin’s lymphoma. The primary outcome with be measured by adverse (negative) side effects, maximum dosage, response rate, and concentration of JCAR017. The...
Read More
